Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06491823 · ClinicalTrials.gov registry record · NA

Speech Motor Learning and Retention (Aim 2)

A NA study of Speech, sponsored by Yale University.

Recruiting
Registry status
NA
Development phase
120
Enrollment target
1
Study location

NCT06491823: Recruiting NA study of Speech, sponsored by Yale University.

NCT06491823 is a NA study of Speech that is actively recruiting participants, run by Yale University. The registered enrollment target is 120 participants, below the 162-participant average among 9 other Speech trials with a reported enrollment target (26% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06491823, a NA study of Speech, is actively recruiting participants, sponsored by Yale University.

RECRUITING
Registry status
NA
Development phase
120 participants
Enrollment target
1
Study location

Study Summary

The overall goal of this research is to test a new model of speech motor learning, whose central hypothesis is that learning and retention are associated with plasticity not only in motor areas of the brain but in auditory and somatosensory regions as well. The strategy for the proposed research is to identify individual brain areas that contribute causally to retention by disrupting their activity with transcranial magnetic stimulation (TMS). Investigators will also use functional magnetic resonance imaging (fMRI) which will enable identification of circuit-level activity which predicts either learning or retention of new movements, and hence test the specific contributions of candidate sensory and motor zones. In other studies, investigators will record sensory and motor evoked potentials over the course of learning to determine the temporal order in which individual sensory and cortical motor regions contribute. The goal here is to identify brain areas in which learning-related plasticity occurs first and which among these areas predict subsequent learning.

Primary Outcome

Audapter software will be used to alter the first and second formant frequencies of the spoken words and this is played back to subjects through headphones. Subjects will be tested both with unaltered feedback and with abruptly introduced frequency shifts.The change in the first (F1) and second format frequency (F2) values will be assessed using Praat.

Conditions Studied

Interventions

  • BEHAVIORAL Adaptation
  • BEHAVIORAL Adaptation baseline
  • DEVICE Motor evoked potentials
  • DEVICE Auditory evoked potentials
  • DEVICE Somatosensory evoked potentials

Study Locations (1)

Connecticut

  • Yale Child Study Center - New Haven

Trial Details

FieldValue
Enrollment Target 120 participants
Start Date 2024-10-01
Est. Completion 2029-05-31
Phase NA
Yale University

1,492 total trials

What NCT06491823 shows while recruiting

NCT06491823 is an interventional study that assigns participants to a tested intervention. The registered 120 participants enrollment target is mid-sized for trials with a published cap, below the 162-participant average among 9 other Speech trials with a reported enrollment target (26% lower).

The record links to 1 condition, with Speech appearing as the primary indexed condition, and to 5 interventions - of which Adaptation is the first listed.

NCT06491823 reports a single indexed study location in Connecticut.

Frequently Asked Questions

What is clinical trial NCT06491823 about?

NCT06491823 is a clinical study titled "Speech Motor Learning and Retention (Aim 2)". The overall goal of this research is to test a new model of speech motor learning, whose central hypothesis is that learning and retention are associated with plasticity not only in motor areas of the brain but in auditory and somatosensory regions as well. The strategy for the proposed research is ...

What is the current status of trial NCT06491823?

This trial is currently recruiting. It is a NA study. The enrollment target is 120 participants. The study started on 2024-10-01. Estimated completion is 2029-05-31.

What conditions does trial NCT06491823 study?

This clinical trial studies the following conditions: Speech.

What interventions are being tested in trial NCT06491823?

The interventions under investigation include: Adaptation (BEHAVIORAL), Adaptation baseline (BEHAVIORAL), Motor evoked potentials (DEVICE), Auditory evoked potentials (DEVICE), Somatosensory evoked potentials (DEVICE).

Who is sponsoring clinical trial NCT06491823?

This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06491823 being conducted?

This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Speech

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06491823's enrollment target sits among peer trials

120 4th of 9 higher than 5 of 9 other Speech trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Speech trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01174108 · 120 participants · Phase 2

    Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells

  • NCT01627301 · 120 participants · NA

    Sympathetic Overactivity in Post-traumatic Stress Disorder

  • NCT02025023 · 120 participants · Phase 3

    Local 5-Fluorouracil Injection for the Treatment of Chalazia: A Prospective, Comparative Study

  • NCT02128906 · 120 participants · Phase 2

    Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06491823, the US trial registry maintained by the National Library of Medicine. NCT06491823 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.